<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277001</url>
  </required_header>
  <id_info>
    <org_study_id>KY2017-279</org_study_id>
    <nct_id>NCT03277001</nct_id>
  </id_info>
  <brief_title>Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD</brief_title>
  <acronym>SUPREME</acronym>
  <official_title>Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AECOPD increases the risk of VTE.VTE prevention is a long way to go for high-risk VTE
      patients in China.The incidence of AECOPD complicated with VTE in Asian population is high
      and the mortality rate is high.Rivaroxaban, a new oral anticoagulant, has been widely used in
      the treatment and prevention of VTE.However the question about the efficacy and safety of new
      oral anticoagulant compared with LMWHs for the prevention of symptomatic VTE and VTE-related
      death post-hospital discharge in high-risk AECOPD patients is still unknown. Thus this study
      is to evaluate if the prophylactic anticoagulation effect by Rivaroxaban is non-inferiority
      than Enoxaprine in high risk AECOPD and to evaluate the safety of using Rivaroxaban to
      prevent VTE in high risk AECOPD comparing with Enoxaprine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The acute exacerbation of COPD increases the risk of venous thromboembolism.VTE prevention is
      a long way to go for high-risk VTE patients in China.The incidence of AECOPD complicated with
      VTE in Asian population is high and the mortality rate is high.Rivaroxaban, a new oral
      anticoagulant, has been widely used in the treatment and prevention of VTE.However the
      question about the efficacy and safety of new oral anticoagulant compared with LMWHs for the
      prevention of symptomatic VTE and VTE-related death post-hospital discharge in high-risk
      AECOPD patients is still unknown. Thus this study is to evaluate if the prophylactic
      anticoagulation effect by Rivaroxaban is non-inferiority than Enoxaprine in high risk AECOPD
      and to evaluate the safety of using Rivaroxaban to prevent VTE in high risk AECOPD comparing
      with Enoxaprine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VTE incidence</measure>
    <time_frame>1 month</time_frame>
    <description>VTE incidence ( include PE and DVT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital Motality</measure>
    <time_frame>1 month</time_frame>
    <description>in-hospital Motality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital duration</measure>
    <time_frame>1 month</time_frame>
    <description>length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of bleeding</measure>
    <time_frame>1 month</time_frame>
    <description>incidence of bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Acute Exacerbation Copd</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score &gt; 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score &gt; 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and &lt; 50 ml/min) po.</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin 40mg IH</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization；Padua
             score &gt; 4；Age from 40-80y

        Exclusion Criteria:

          -  Patients whose admitting diagnosis was VTE；Patients whose duration of hospital stay
             was &lt;3 days or &gt;30 days ；Patients who received therapeutic doses of anticoagulants or
             thrombolytic therapy for any indication before hospitalization；an organic lesion that
             could bleed; severe liver or renal failure; confirmed or uncontrolled hypertension; a
             congenital or acquired coagulation disorder; a history of hypersensitivity or
             thrombocytopenia to heparins of any type；Patients who were contraindicated to
             anticoagulant therapy, venography, or angiography
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengqing Li, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengqing Li, Ph D</last_name>
    <phone>86-021-52887072</phone>
    <email>shengqingli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Gong, Ph D</last_name>
    <phone>86-021-52887072</phone>
    <email>gongyi1978@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan hospital,Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Aleva FE, Voets LWLM, Simons SO, de Mast Q, van der Ven AJAM, Heijdra YF. Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD: A Systematic Review and Meta-analysis. Chest. 2017 Mar;151(3):544-554. doi: 10.1016/j.chest.2016.07.034. Epub 2016 Aug 12. Review.</citation>
    <PMID>27522956</PMID>
  </reference>
  <reference>
    <citation>Wang F, Cheng ZZ, Wang JL, Han WZ, Sun NN. [Incidence of pulmonary embolism in patients with acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis]. Zhonghua Yi Xue Za Zhi. 2013 Jun 25;93(24):1868-71. Chinese.</citation>
    <PMID>24124736</PMID>
  </reference>
  <reference>
    <citation>Akpinar EE, Hoşgün D, Akpinar S, Ataç GK, Doğanay B, Gülhan M. Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol. 2014 Jan-Feb;40(1):38-45. doi: 10.1590/S1806-37132014000100006. English, Portuguese.</citation>
    <PMID>24626268</PMID>
  </reference>
  <reference>
    <citation>Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.</citation>
    <PMID>26867832</PMID>
  </reference>
  <reference>
    <citation>Chen CY, Liao KM. The Incidence of Deep Vein Thrombosis in Asian Patients With Chronic Obstructive Pulmonary Disease. Medicine (Baltimore). 2015 Nov;94(44):e1741. doi: 10.1097/MD.0000000000001741.</citation>
    <PMID>26554770</PMID>
  </reference>
  <reference>
    <citation>EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.</citation>
    <PMID>22449293</PMID>
  </reference>
  <reference>
    <citation>Ageno W, Mantovani LG, Haas S, Kreutz R, Haupt V, Schneider J, Turpie AG. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thromb J. 2014 Jul 14;12:16. doi: 10.1186/1477-9560-12-16. eCollection 2014.</citation>
    <PMID>25093014</PMID>
  </reference>
  <reference>
    <citation>Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.</citation>
    <PMID>23388003</PMID>
  </reference>
  <reference>
    <citation>Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203. Epub 2011 Oct 24.</citation>
    <PMID>22023098</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Shengqing Li</investigator_full_name>
    <investigator_title>Chief physician, Professor-levelled doctor</investigator_title>
  </responsible_party>
  <keyword>AECOPD</keyword>
  <keyword>VTE prevention</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>LMWHs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

